Compare MDXH & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDXH | MIST |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | Belgium | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.4M | 176.3M |
| IPO Year | 2021 | N/A |
| Metric | MDXH | MIST |
|---|---|---|
| Price | $3.82 | $1.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $7.67 | ★ $8.50 |
| AVG Volume (30 Days) | 151.4K | ★ 3.4M |
| Earning Date | 02-26-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $103,069,000.00 | N/A |
| Revenue This Year | $23.34 | N/A |
| Revenue Next Year | $22.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.68 | N/A |
| 52 Week Low | $1.35 | $0.63 |
| 52 Week High | $5.33 | $3.06 |
| Indicator | MDXH | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 55.75 | 41.12 |
| Support Level | $3.56 | $1.97 |
| Resistance Level | $4.34 | $2.06 |
| Average True Range (ATR) | 0.27 | 0.12 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 61.19 | 18.75 |
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).